Bortezomib in Late Antibody-mediated Kidney Transplant Rejection
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2018
Price : $35 *
At a glance
- Drugs Bortezomib (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms BORTEJECT
- 06 Jun 2018 Results presented at the 2018 American Transplant Congress
- 22 Mar 2017 Status changed from active, no longer recruiting to completed.
- 03 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.